Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has approved ALYFTREK (vanzacaftor/tezacaftor ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

The money will pay salaries for civilian government and school employees, healthcare workers and first responders.The new military aid comes as Russia has launched a barrage of attacks against ...

The makers had already announced that the teaser of this upcoming film would be released on Salman Khan's 2024 birthday but even before that, the actor has shared a new poster with his fans.

On Thursday, Salman took to social media: Instagram and Twitter to share the first poster which gives a glimpse of his look in the film. He shared that the teaser will drop tomorrow. The newly ...

Vertex Pharmaceuticals (NASDAQ: VRTX) fell by 13% on Dec. 19, when the rare-disease drug developer reported some lackluster results from a late-stage clinical trial. But far from being a reason to ...

Vertex Pharmaceuticals is trying to diversify its product portfolio. One of the programs it's working on aims to treat pain in a few contexts. There's reason to believe that it won't be effective ...

In December 2024, Ukraine signed memorandums to receive tranches of a loan backed by Russian immobilized assets (ERA loan) and received financial aid from the EU, IMF and the US through the World Bank ...

In this article, we are going to take a look at where Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) stands against the other stocks that will make you rich in 2025. Jurrien Timmer, Director of ...

H.C. Wainwright has recently reiterated Vertex Pharmaceuticals Inc (VRTX) stock to Buy rating, as announced on December 20, 2024, according to Finviz. Earlier, on December 19, 2024, Oppenheimer had ...

Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $408.18, moving +0.72% from the previous trading session. The stock trailed the S&P 500, which registered a daily gain of 1.1%.

Senores Pharmaceuticals IPO Allotment Today: At the upper price band, the company is valued at a P/E of 55x with a market cap of Rs 1800.6 crore (Image: Freepik) Senores Pharmaceuticals IPO closes ...